stockmarketproxy
/
SMMTNasdaq SEC EDGAR

Summit Therapeutics Inc.

Pharmaceutical Preparations·MIAMI, FL·FY end 12/31·CIK 1599298
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue—$0$0$705.0K$1.8M
Gross Profit——————
Operating Income—-$226.0M-$609.6M-$72.1M-$86.2M
Net Income-$1.1B-$221.3M-$614.9M-$78.8M-$88.6M
Operating CF-$322.9M-$142.1M-$76.8M-$41.6M-$72.6M
Capex$657.0K$139.0K$128.0K$624.0K$306.0K
Free Cash Flow-$323.6M-$142.2M-$76.9M-$42.2M-$72.9M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin———-10225.4%-4764.3%
Net Margin———-11174.8%-4897.8%
FCF Margin———-5986.7%-4029.5%
R&D / Revenue———7375.7%4718.2%
Effective Tax0.0%———0.0%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
SMMT
489:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
SMMT
$0M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
SMMT
—
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%